Design of peptide substrate for sensitively and specifically detecting Two Aβ-degrading enzymes: Neprilysin and angiotensin-converting enzyme

Po Ting Chen, Chao Long Chen, Lilian Tsai Wei Lin, Chun Hsien Lo, Chaur Jong Hu, Rita P Y Chen, Steven S S Wang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Upregulation of neprilysin (NEP) to reduce Aβ accumulation in the brain is a promising strategy for the prevention of Alzheimer's disease (AD). This report describes the design and synthesis of a quenched fluorogenic peptide substrate qf-Aβ(12-16)AAC (with the sequence VHHQKAAC), which has a fluorophore, Alexa-350, linked to the side-chain of its C-terminal cysteine and a quencher, Dabcyl, linked to its N-terminus. This peptide emitted strong fluorescence upon cleavage. Our results showed that qf-Aβ(12-16)AAC is more sensitive to NEP than the previously reported peptide substrates, so that concentrations of NEP as low as 0.03 nM could be detected at peptide concentration of 2 μM. Moreover, qf-Aβ(12-16)AAC had superior enzymatic specificity for both NEP and angiotensin-converting enzyme (ACE), but was inert with other Aβ-degrading enzymes. This peptide, used in conjunction with a previously reported peptide substrate qf-Aβ(1-7)C [which is sensitive to NEP and insulin-degrading enzyme (IDE)], could be used for high-throughput screening of compounds that only upregulate NEP. The experimental results of cell-based activity assays using both qf-Aβ(1-7)C and qf-Aβ(12-16)AAC as the substrates confirm that somatostatin treatment most likely upregulates IDE, but not NEP, in neuroblastoma cells.

Original languageEnglish
Article numbere0153360
JournalPLoS One
Volume11
Issue number4
DOIs
Publication statusPublished - Apr 1 2016

Fingerprint

Neprilysin
peptidyl-dipeptidase A
Peptidyl-Dipeptidase A
peptides
Peptides
Substrates
Enzymes
enzymes
Insulysin
Up-Regulation
insulin
somatostatin
fluorescent dyes
Alzheimer disease
Fluorophores
cysteine
Somatostatin
Neuroblastoma
Fluorescent Dyes
Cysteine

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Design of peptide substrate for sensitively and specifically detecting Two Aβ-degrading enzymes : Neprilysin and angiotensin-converting enzyme. / Chen, Po Ting; Chen, Chao Long; Lin, Lilian Tsai Wei; Lo, Chun Hsien; Hu, Chaur Jong; Chen, Rita P Y; Wang, Steven S S.

In: PLoS One, Vol. 11, No. 4, e0153360, 01.04.2016.

Research output: Contribution to journalArticle

Chen, Po Ting ; Chen, Chao Long ; Lin, Lilian Tsai Wei ; Lo, Chun Hsien ; Hu, Chaur Jong ; Chen, Rita P Y ; Wang, Steven S S. / Design of peptide substrate for sensitively and specifically detecting Two Aβ-degrading enzymes : Neprilysin and angiotensin-converting enzyme. In: PLoS One. 2016 ; Vol. 11, No. 4.
@article{d6288d8738814ebfabf79cd6d6522fd8,
title = "Design of peptide substrate for sensitively and specifically detecting Two Aβ-degrading enzymes: Neprilysin and angiotensin-converting enzyme",
abstract = "Upregulation of neprilysin (NEP) to reduce Aβ accumulation in the brain is a promising strategy for the prevention of Alzheimer's disease (AD). This report describes the design and synthesis of a quenched fluorogenic peptide substrate qf-Aβ(12-16)AAC (with the sequence VHHQKAAC), which has a fluorophore, Alexa-350, linked to the side-chain of its C-terminal cysteine and a quencher, Dabcyl, linked to its N-terminus. This peptide emitted strong fluorescence upon cleavage. Our results showed that qf-Aβ(12-16)AAC is more sensitive to NEP than the previously reported peptide substrates, so that concentrations of NEP as low as 0.03 nM could be detected at peptide concentration of 2 μM. Moreover, qf-Aβ(12-16)AAC had superior enzymatic specificity for both NEP and angiotensin-converting enzyme (ACE), but was inert with other Aβ-degrading enzymes. This peptide, used in conjunction with a previously reported peptide substrate qf-Aβ(1-7)C [which is sensitive to NEP and insulin-degrading enzyme (IDE)], could be used for high-throughput screening of compounds that only upregulate NEP. The experimental results of cell-based activity assays using both qf-Aβ(1-7)C and qf-Aβ(12-16)AAC as the substrates confirm that somatostatin treatment most likely upregulates IDE, but not NEP, in neuroblastoma cells.",
author = "Chen, {Po Ting} and Chen, {Chao Long} and Lin, {Lilian Tsai Wei} and Lo, {Chun Hsien} and Hu, {Chaur Jong} and Chen, {Rita P Y} and Wang, {Steven S S}",
year = "2016",
month = "4",
day = "1",
doi = "10.1371/journal.pone.0153360",
language = "English",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - Design of peptide substrate for sensitively and specifically detecting Two Aβ-degrading enzymes

T2 - Neprilysin and angiotensin-converting enzyme

AU - Chen, Po Ting

AU - Chen, Chao Long

AU - Lin, Lilian Tsai Wei

AU - Lo, Chun Hsien

AU - Hu, Chaur Jong

AU - Chen, Rita P Y

AU - Wang, Steven S S

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Upregulation of neprilysin (NEP) to reduce Aβ accumulation in the brain is a promising strategy for the prevention of Alzheimer's disease (AD). This report describes the design and synthesis of a quenched fluorogenic peptide substrate qf-Aβ(12-16)AAC (with the sequence VHHQKAAC), which has a fluorophore, Alexa-350, linked to the side-chain of its C-terminal cysteine and a quencher, Dabcyl, linked to its N-terminus. This peptide emitted strong fluorescence upon cleavage. Our results showed that qf-Aβ(12-16)AAC is more sensitive to NEP than the previously reported peptide substrates, so that concentrations of NEP as low as 0.03 nM could be detected at peptide concentration of 2 μM. Moreover, qf-Aβ(12-16)AAC had superior enzymatic specificity for both NEP and angiotensin-converting enzyme (ACE), but was inert with other Aβ-degrading enzymes. This peptide, used in conjunction with a previously reported peptide substrate qf-Aβ(1-7)C [which is sensitive to NEP and insulin-degrading enzyme (IDE)], could be used for high-throughput screening of compounds that only upregulate NEP. The experimental results of cell-based activity assays using both qf-Aβ(1-7)C and qf-Aβ(12-16)AAC as the substrates confirm that somatostatin treatment most likely upregulates IDE, but not NEP, in neuroblastoma cells.

AB - Upregulation of neprilysin (NEP) to reduce Aβ accumulation in the brain is a promising strategy for the prevention of Alzheimer's disease (AD). This report describes the design and synthesis of a quenched fluorogenic peptide substrate qf-Aβ(12-16)AAC (with the sequence VHHQKAAC), which has a fluorophore, Alexa-350, linked to the side-chain of its C-terminal cysteine and a quencher, Dabcyl, linked to its N-terminus. This peptide emitted strong fluorescence upon cleavage. Our results showed that qf-Aβ(12-16)AAC is more sensitive to NEP than the previously reported peptide substrates, so that concentrations of NEP as low as 0.03 nM could be detected at peptide concentration of 2 μM. Moreover, qf-Aβ(12-16)AAC had superior enzymatic specificity for both NEP and angiotensin-converting enzyme (ACE), but was inert with other Aβ-degrading enzymes. This peptide, used in conjunction with a previously reported peptide substrate qf-Aβ(1-7)C [which is sensitive to NEP and insulin-degrading enzyme (IDE)], could be used for high-throughput screening of compounds that only upregulate NEP. The experimental results of cell-based activity assays using both qf-Aβ(1-7)C and qf-Aβ(12-16)AAC as the substrates confirm that somatostatin treatment most likely upregulates IDE, but not NEP, in neuroblastoma cells.

UR - http://www.scopus.com/inward/record.url?scp=84978876470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978876470&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0153360

DO - 10.1371/journal.pone.0153360

M3 - Article

C2 - 27096746

AN - SCOPUS:84978876470

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e0153360

ER -